Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Phreesia executive sells over $94k in company stock

Published 2024-04-10, 05:24 p/m
PHR
-

Phreesia, Inc. (NYSE:PHR) has recently filed an SEC Form 4 report detailing a series of stock transactions by SVP of Life Sciences, David Linetsky. According to the document, Linetsky sold a total of $94,122 worth of company stock.

The transactions, which occurred on April 8, 2024, involved the sale of Phreesia common stock at prices ranging from $22.00 to $23.04 per share. Specifically, the weighted average prices for the shares were reported as $22.6161 and $23.0163 for different batches of the stock sold.

The filing indicates that the sales were part of a mandatory sell-to-cover policy that the company has in place to handle tax withholding obligations connected to the settlement of restricted stock units. This policy is designed to automatically sell a portion of vested shares to cover the taxes due, and is a common practice within publicly traded companies.

Linetsky's transactions resulted in a decrease in his direct holdings, but he still retains a substantial number of shares in the company. The Form 4 did not report any purchases of stock by Linetsky during this period.

Investors often monitor insider transactions as they can provide insights into executives' perspectives on the company's current valuation and future prospects. However, it's important to note that these transactions do not always indicate a change in company fundamentals or executives' long-term outlook.

Phreesia, Inc. provides a range of software solutions to healthcare organizations, aiming to improve the patient experience and streamline administrative tasks. The company's shares are publicly traded on the New York Stock Exchange under the ticker symbol PHR.

InvestingPro Insights

As Phreesia, Inc. (NYSE:PHR) navigates the market following the insider transactions by SVP of Life Sciences David Linetsky, investors may be curious about the company's financial health and future outlook. According to InvestingPro, the company operates with a moderate level of debt and has not been profitable over the last twelve months, with analysts not anticipating profitability this year. Additionally, Phreesia does not pay a dividend to shareholders, which may influence investment strategies focused on income generation.

InvestingPro Data paints a detailed picture of Phreesia's financial metrics as of the last twelve months ending in Q4 2024. The company's market capitalization stands at $1.31 billion, reflecting investor valuation of the company. Despite a significant revenue growth of 26.84% during this period, the company's P/E ratio remains negative at -9.96, indicating that it is not generating net earnings currently. Furthermore, the gross profit margin is reported at a healthy 65.19%, suggesting that while profitability is elusive, the company is effective at controlling the cost of goods sold relative to its sales.

Investors considering Phreesia's stock should note that there are 4 additional InvestingPro Tips available, which could provide deeper insights into the company's performance and potential. For those looking to delve further into these metrics and tips, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.